Incannex Healthcare Limited Sponsored ADR (IXHL)
NASDAQ:IXHL
Want to see IXHL full AI Analyst Report?
IXHL Stock Chart & Stats
$0.39
-$0.11(-5.37%)
At close: 4:00 PM EST
$0.39
-$0.11(-5.37%)
Day’s Range― - ―
52-Week Range$2.40 - $49.80
Previous CloseN/A
Volume10.98K
Average Volume (3M)644.81K
Market Cap
$50.72M
Enterprise Value-$27.05M
Total Cash (Recent Filing)$68.90M
Total Debt (Recent Filing)$163.00K
Price to Earnings (P/E)―
Beta3.70
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding13,973,663
10 Day Avg. Volume430,983
30 Day Avg. Volume644,808
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.55
Price to Sales (P/S)86.40
P/FCF Ratio-0.59
Enterprise Value/Market Cap-0.53
Enterprise Value/Revenue-406.02
Enterprise Value/Gross Profit-406.02
Enterprise Value/Ebitda0.59
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.2
Revenue Forecast (FY)$700.00K
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA strong cash position (~$75M) with no debt materially reduces near-term financing pressure and supports clinical funding into 2027. This durability gives management flexibility to execute dose-optimization and Phase 3 planning while limiting interest burden and restrictive covenants.
Clinical Momentum & Regulatory SupportFast Track designation and positive Phase 2 results for IHL-42X signal regulatory prioritization and de-risk key development milestones. A funded pathway into an optimized Phase 3 enhances the probability of eventual approval in a large, underserved obstructive sleep apnea market.
Scientific & Advisory StrengthBuilding and expanding clinical advisory boards for PSX-001 enhances trial design, endpoint selection and regulatory strategy. Independent expert governance improves execution quality, reducing development risk and strengthening the company’s scientific credibility over the medium term.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow (≈-$12.5M in 2025) indicates the business continues to consume capital to fund trials. Even with reduced burn versus prior years, sustained negative cash generation implies ongoing financing reliance until commercial revenue or positive operating margins emerge.
Minimal Revenue & UnprofitabilityRevenue is effectively negligible despite a rebound, while operating and net margins remain deeply negative. This underscores an early-stage commercial profile: meaningful product revenues are distant, so long-term value depends on successful late-stage trials and eventual market uptake, not current sales.
Dependence On Equity FinancingThe company has historically relied on equity issuance (ATM and registered offerings) to fund operations. While current cash is robust, continued development will likely require future capital absent profitability, creating dilution and execution risk if capital markets tighten or investor appetite wanes.
Incannex Healthcare Limited Sponsored ADR News
IXHL FAQ
What was Incannex Healthcare Limited Sponsored ADR’s price range in the past 12 months?
Incannex Healthcare Limited Sponsored ADR lowest stock price was $2.40 and its highest was $49.80 in the past 12 months.
What is Incannex Healthcare Limited Sponsored ADR’s market cap?
Incannex Healthcare Limited Sponsored ADR’s market cap is $50.72M.
When is Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date?
Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date is Sep 02, 2026 which is in 139 days.
How were Incannex Healthcare Limited Sponsored ADR’s earnings last quarter?
Incannex Healthcare Limited Sponsored ADR released its earnings results on Mar 02, 2026. The company reported -$0.6 earnings per share for the quarter, the consensus estimate of -$0.6 by $0.
Is Incannex Healthcare Limited Sponsored ADR overvalued?
According to Wall Street analysts Incannex Healthcare Limited Sponsored ADR’s price is currently Overvalued.
Does Incannex Healthcare Limited Sponsored ADR pay dividends?
Incannex Healthcare Limited Sponsored ADR does not currently pay dividends.
What is Incannex Healthcare Limited Sponsored ADR’s EPS estimate?
Incannex Healthcare Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Incannex Healthcare Limited Sponsored ADR have?
Incannex Healthcare Limited Sponsored ADR has 13,973,663 shares outstanding.
What happened to Incannex Healthcare Limited Sponsored ADR’s price movement after its last earnings report?
Incannex Healthcare Limited Sponsored ADR reported an EPS of -$0.6 in its last earnings report, expectations of -$0.6. Following the earnings report the stock price went down -9.906%.
Which hedge fund is a major shareholder of Incannex Healthcare Limited Sponsored ADR?
Currently, no hedge funds are holding shares in IXHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incannex Healthcare Limited Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
IXHL Sentiment 70%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.84%
12-Months-Change
Fundamentals
Return on Equity
-199.09%
Trailing 12-Months
Asset Growth
575.36%
Trailing 12-Months
Company Description
Incannex Healthcare Limited Sponsored ADR
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Technical Analysis
Assertio Therapeutics
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―